ENGAGE run · f58d7f3b97cb

```json [ { "post_index": 5, "cluster_ids": [20, 16], "claim": "Wearable heart rate tracking enables early detection before clinical diagnosis occurs", "argument_type": "mechanism_explanation", "stance": "supports_status_quo", "hyde_excerpt": "Wearable devices that continuously monitor heart rate variability, rhythm patterns, and sleep-activity correlations create a new i

```json [ { "post_index": 22, "matched_article_id": 519, "match_confidence": 85, "match_reason": "Tweet argues that insurance coverage gaps force GLP-1 patients to choose between paying now vs waiting for next-gen therapies — article directly analyzes how commercial insurers and PBMs are building access-management operating systems around GLP-1 coverage, including the persistence

The "wait for next-gen" framing assumes the access problem gets solved by a better molecule. It probably doesn't. What I've been tracking is how the coverage gap isn't primarily a pricing problem, it's an operational one. Employers covering GLP-1s without structured access management, adherence support, and outcomes accountability are seeing 59% higher-than-expected utilization with costs they ca

The result makes sense, but the mechanism behind it is more specific than it looks. VA Whole Health didn't outperform CBT because integrative care is clinically superior in some general sense. It scaled because CARA created reimbursement authority that no other health system has. The payment infrastructure was already in place. CBT in primary care still runs into visit architecture problems, codi

Malaria is the case that breaks every optimistic narrative about trial efficiency. The bottleneck story there isn't purely commercial, though. When I dug into what FDA's Real Time Clinical Trial program actually destroys structurally, the finding that stopped me was this: roughly 45 percent of drug development time is administrative dead time, batch submission latency, review queues, nothing biol

The IMG-friendliness of newer programs is real, but the match advantage may be shorter-lived than applicants expect. The 2025 NRMP data already shows 44,000 applicants competing for 41,000 PGY-1 slots, and surgical specialties carry some of the steepest competition curves in that pool. New programs absorb some pressure at the margins, but they don't change the underlying supply-demand ratio. The

```json [] ```

[]

```json [ {"post_index": 0, "prediction": "approve", "confidence": 72, "reason": "AI workforce disruption with healthcare specificity (content moderation jobs lost); connects hardware deployment to healthcare worker impacts"}, {"post_index": 1, "prediction": "reject", "confidence": 88, "reason":

```json [ { "category": "ai_safety_vulnerability_incident_tangent", "summary": "Posts about AI safety vulnerabilities, security breaches, or agent failures that lack healthcare application context", "exclusion_rule": "Exclude posts that focus on AI safety incidents, security vulnerabil